Last reviewed · How we verify
NCT07507591
Safety, Efficacy, and Short-Term Outcomes of Rezūm Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia Under Local Anesthesia With Intravenous Sedation: A Single-Center Retrospective Study of 129 Patients in the Kurdistan Region of Iraq
trial testing Rezum Water Vapor Thermal Therapy in Benign Prostate Hyperplasia in 129 participants. Completed in 12 March 2026.
12 March 2026
Quick facts
| Lead sponsor | ALI KAMAL M. SAMI |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 129 |
| Start date | 3 September 2025 |
| Primary completion | 12 March 2026 |
| Estimated completion | 12 March 2026 |
| Sites | 1 location across Iraq |
Drugs / interventions tested
- Rezum Water Vapor Thermal Therapy
Conditions studied
- Benign Prostate Hyperplasia — all drugs for Benign Prostate Hyperplasia →
Sponsor
ALI KAMAL M. SAMI — full company profile →
Who can join
Adults 45 to 96, male only, with Benign Prostate Hyperplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This single-center retrospective study evaluates the safety, feasibility, and short-term clinical outcomes of Rezūm water vapor thermal therapy (WVTT) for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in patients treated under local anesthesia with intravenous sedation. The study was conducted at Royal Hospital, Sulaymaniyah, Kurdistan Region of Iraq, and includes 129 consecutive patients aged 45 to 96 years with prostate volumes ranging from 30 to 120 grams. Outcomes assessed include symptom improvement, urinary flow, post-void residual volume, quality of life, erectile function, prostate volume reduction, catheter-related outcomes, perioperative complications, and retreatment rates. This study aims to provide real-world evidence regarding the use of Rezūm therapy in a high-comorbidity population and in a Middle Eastern clinical setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07507591
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Benign Prostate Hyperplasia
Currently open trials in the same condition.
- NCT07071207 — Effect of Text Message Reminders on M-ISI Score After Prostate Surgery · NA · recruiting
- NCT07283484 — Early Versus Delayed Trial Without Catheter in Men With Acute Urinary Retention. · NA · recruiting
- NCT07014969 — En-bloc With Early Apical Release Versus Lobe-by-lobe LASER Enucleation of the Prostate · NA · active not recruiting
Other ALI KAMAL M. SAMI trials
Trials by the same sponsor.
- NCT04082351 — Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients. · NA · completed
- NCT06677177 — The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms · NA · completed
- NCT06681116 — Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07507591 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ALI KAMAL M. SAMI
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07507591.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing